Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 6155
- Evidence Id
- 6155
- Core Evidence Id
- 6155
- Source Clinical Trial Id
- 6139
- Herb2 Clinical Trial Id
- HBCT006139
- Nct Id
- NCT03062449
- Title
- Phase IIa L-serine Trial for eAD
- Status
- Terminated
- Phase
- Phase 2
- Study Result
- Yes
- Study Condition
- Alzheimer Disease
- Study Type
- Interventional
- Study Design
- Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
- Intervention
- DRUG: L-Serine|OTHER: Placebo Gummy
- Intervention Allocation
- Randomized
- Intervention Model
- Parallel
- Intervention Mask
- Quadruple
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Child, Adult, Older_Adult
- Enrollment
- 29
- Outcome Measure
- Change in Score on the Montreal Cognitive Assessment Assessment Evaluation, Cognitive Assessment will be performed and score obtained at clinical trial visits. The Montreal Cognitive Assessment or The MoCA Test is a highly sensitive tool for early detection of mild cognitive impairment. The assessment evaluates eight domains of cognitive functions, including visuospatial and executive function, naming, memory, attention, language, abstraction, and orientation. Scores on the MoCA range from 0 to 30. A score less than 26 is considered as mild cognitive impairment. Higher values represent a better outcome., Baseline, 6 Months, 9 Months
- Sponsor Collaborator
- Aleksandra Stark|Brain Chemistry Labs, Institute for Ethnomedicine
- Funded By
- OTHER
- Location
- Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States
- Other Id
- D16180
- Start Date
- 2017-03-01
- Primary Completion Date
- 2021-07-20
- Completion Date
- 2021-07-20
- First Posted
- 2017-02-23
- Results First Posted
- 2024-07-03
- Last Update Posted
- 2024-07-03
- Study Document
- Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/49/NCT03062449/Prot_SAP_000.pdf
- Study Url
- https://clinicaltrials.gov/study/NCT03062449
- Title Cn
- Title En
- Phase IIa L-serine Trial for eAD
- Bilingual Status
- semi_complete